



Public

Environmental and Social Data Sheet¹

Overview

Project Name:	WISENEURO (IEU TI)
Project Number:	2023-0439
Country:	Italy
Project Description:	The promoter is a medical device innovator focusing on neuromonitoring and neuromodulation devices. The project will support investments in research, development and innovation (RDI) to accelerate the advancement and developments of its product portfolio, thereby expanding the promoter's ability to improve patient outcomes.
EIA required:	no
Invest EU sustainability proofing required	yes
Project included in Carbon Footprint Exercise ² :	no

Environmental and Social Assessment

Environmental Assessment

The Promoter is a medical technology company focused on the development and commercialization of neuromonitoring and neuromodulation devices for applications in neurosurgery and spinal cord stimulation.

The project concerns investments in research and development activities, carried out by the Promoter and its partners in existing facilities without changing their already authorised scope. The project is not listed under Annex I nor Annex II of the EIA Directive 2011/92/EU amended by Directive 2014/52/EU, so the project is not subject to an EIA Screening or an EIA procedure.

Climate Assessment

Research and development activities, such as those present in this project, neither present significant negative nor positive impacts for climate aspects.

The project has been assessed for Paris alignment and is considered to be aligned both against low carbon and resilience goals against the policies set out in the Climate Bank Roadmap.

¹ The information contained in the document reflects the requirement related to the environmental, social and climate information to be provided to Investment Committee as required by the Invest EU Regulation and it represents the equivalent of the information required in the template of the InvestEU sustainability proofing summary

² Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO₂e/year absolute (gross) or 20,000 tonnes CO₂e/year relative (net) – both increases and savings.



The Promoter is in scope but screened out of the PATH framework as it does not operate in a high emitting sector and is not considered as a highly vulnerable counterpart.

Social Assessment

If successful, the project is expected to lead to important social benefits, considering the targeted indications and the level of unmet medical need. Furthermore, the project contributes to positive social impacts, as the Promoter is expected to carry out its activities in compliance with applicable local labour and social standards.

Other Environmental and Social Aspects

The Quality Management System (QMS) of the promoter is based on EN ISO 13485:2016 and has been certified by a relevant Notified Body. The QMS is maintained compliant with all MedTech (medical device) related regulations, guidelines, and industry standards.

For pre-clinical and clinical trials, the Promoter retains the services of subcontractors (such as Clinical Research Organisations) and relies on their official policies, processes, and qualifications, considering the high level of scrutiny and responsibility involved in such operations.

The Promoter is committed to animal welfare and the responsible use of animals for scientific purposes, ensuring that pre-clinical activities, whether performed directly or by subcontractors, comply with the European Directive 2010/63/EU and/or international equivalent standards on the protection of animals used for scientific purposes, where applicable.

Through the R&D activities and investments, the Promoter is also expected to sustain its current level of skilled personnel, while contributing to European scientific innovation, hence fostering and nurturing the vital research community.

Conclusions and Recommendations

The project's activities are not listed by EIA Directive 2011/92/EU amended by Directive 2014/52/EU. The research activities will be executed in existing and already authorised research facilities, expected to be in compliance with all applicable EU environmental legislation.

The project is not expected to generate significant negative environmental or social impacts.

Sustainability proofing conclusion: The Project is carried out in compliance with applicable national and EU environmental and social legislation. Based on the environmental, climate and social information and based on the review of the likely significant environmental, climate and social risks and impacts and the mitigation measures and management systems in place, the Project is deemed to have low residual environmental, climate and social risks and impacts. No further sustainability proofing is therefore required.

Considering the above, the project is considered acceptable for Bank financing in environmental and social terms.